Target Binding Site Detail
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T31825 | Target Info | |||
Target Name | Hemoglobin subunit beta (HBB) | ||||
Synonyms | LVVhemorphin7; Hemoglobin beta chain; Betaglobin; Beta-globin | ||||
Target Type | Clinical trial Target | ||||
Gene Name | HBB | ||||
Biochemical Class | Pore-forming globin | ||||
UniProt ID |
Ligand General Information | Top | ||||
---|---|---|---|---|---|
Ligand Name | Sphingosine-1-phosphate | Ligand Info | |||
Canonical SMILES | CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N)O | ||||
InChI | 1S/C18H38NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h14-15,17-18,20H,2-13,16,19H2,1H3,(H2,21,22,23)/b15-14+/t17-,18+/m0/s1 | ||||
InChIKey | DUYSYHSSBDVJSM-KRWOKUGFSA-N | ||||
PubChem Compound ID | 5283560 |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
PDB ID: 5KSI Crystal structure of deoxygenated hemoglobin in complex with sphingosine phosphate and 2,3-Bisphosphoglycerate | ||||||
Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | No | [1] |
PDB Sequence |
VHLTPEEKSA
10 VTALWGKVNV20 DEVGGEALGR30 LLVVYPWTQR40 FFESFGDLST50 PDAVMGNPKV 60 KAHGKKVLGA70 FSDGLAHLDN80 LKGTFATLSE90 LHCDKLHVDP100 ENFRLLGNVL 110 VCVLAHHFGK120 EFTPPVQAAY130 QKVVAGVANA140 LAHKYH
|
|||||
|
||||||
PDB ID: 5KSJ Crystal structure of deoxygenated hemoglobin in complex with Sphingosine phosphate | ||||||
Method | X-ray diffraction | Resolution | 2.40 Å | Mutation | No | [1] |
PDB Sequence |
VHLTPEEKSA
10 VTALWGKVNV20 DEVGGEALGR30 LLVVYPWTQR40 FFESFGDLST50 PDAVMGNPKV 60 KAHGKKVLGA70 FSDGLAHLDN80 LKGTFATLSE90 LHCDKLHVDP100 ENFRLLGNVL 110 VCVLAHHFGK120 EFTPPVQAAY130 QKVVAGVANA140 LAHKYH
|
|||||
|
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Sci Rep. 2017 Nov 10;7(1):15281. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.